Gastroesophageal Junction Adenocarcinoma clinical trials at UCSD

• A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

  open to eligible people ages 18 years and up

  This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

  San Diego, California and other locations

• A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

  open to eligible people ages 18 years and up

  This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

  Encinitas, California and other locations

• A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

  open to eligible people ages 18 years and up

  This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.

  San Diego, California and other locations

Last updated: October 8, 2020